COMUNICADO: Global Strategic Partners Merck and Pfizer Finalize Agreement to Co-Promote XALKORI® (crizotinib) (y 2)

 

COMUNICADO: Global Strategic Partners Merck and Pfizer Finalize Agreement to Co-Promote XALKORI® (crizotinib) (y 2)

Publicado 07/04/2015 14:01:22CET

Merck of Darmstadt, Germany, is a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials. The company has six businesses - Biopharmaceuticals, Consumer Health, Allergopharma, Biosimilars, Life Science and Performance Materials - and generated sales of EUR 11.3 billion in 2014. Around 39,000 employees work in 66 countries to improve the quality of life for patients, to foster the success of customers and to help meet global challenges. Merck is the world's oldest pharmaceutical and chemical company - since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70% interest, the founding family remains the majority owner of the company to this day. Merck holds the global rights to the Merck name and brand. The only exceptions are Canada and the United States, where the company operates as EMD Serono, EMD Millipore and EMD Performance Materials.

All Merck press releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to http://www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.

Pfizer Disclosure Notice

The information contained in this release is as of April 7, 2015. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about an agreement between Pfizer and Merck to co-promote Pfizer's XALKORI in certain markets as well as about the companies' immuno-oncology alliance involving avelumab and Pfizer's anti-PD-1 antibody and clinical development plans, including their potential benefits, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, uncertainties regarding the success of the co-promotion arrangement and whether the companies will realize the anticipated benefits of the co-promotion arrangement; the uncertainties inherent in research and development, including the ability to meet anticipated clinical study commencement and completion dates as well as the possibility of unfavorable study results; risks associated with interim data, including the risk that the final results of the Phase I study for avelumab and/or additional clinical trials may be different from (including less favorable than) the interim data results and may not support further clinical development; the risk that clinical trial data are subject to differing interpretations, and, even when we view data as sufficient to support the safety and/or effectiveness of a product candidate, regulatory authorities may not share our views and may require additional data or may deny approval altogether; whether and when drug applications may be filed in any jurisdictions for any potential product candidates or combination therapies; whether and when any such applications may be approved by regulatory authorities, which will depend on the assessment by such regulatory authorities of the benefit-risk profile suggested by the totality of the efficacy and safety information submitted; decisions by regulatory authorities regarding labeling and other matters that could affect the availability or commercial potential of any of such product candidates or combination therapies; and competitive developments.

A further description of risks and uncertainties can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2014 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned "Risk Factors" and "Forward-Looking Information That May Affect Future Results", as well as in its subsequent reports on Form 8-K, all of which are filed with the SEC and available at http://www.sec.gov and http://www.pfizer.com.

References


1) American Cancer Society. (2011). Global Facts & Figures Second Edition.
Retrieved from:
http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-027766.pdf
2) American Cancer Society. (2014). Lung Cancer (Non-Small Cell) [Fact sheet].
Retrieved from:
http://www.cancer.org/acs/groups/cid/documents/webcontent/003115-pdf.pdf
3) Blumenschein, G. R., Paulus, R., Curran, W. J., Robert, F., Fossella, F.,
Werner-Wasik, M., Herbst, R. S., Doescher, P. O., Choy, H., & Komaki, R. (2011). Phase
II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B
non-small-cell lung cancer: RTOG 0324. Journal of clinical oncology: official journal
of the American Society of Clinical Oncology, 17, 2312-2318.
4) Wood, S. L., Pernemalm, M., Crosbie, P. A., & Whetton, A. D. (2013). The role
of the tumor-microenvironment in lung cancer-metastasis and its relationship to
potential therapeutic targets. Cancer treatment reviews, 4,558-566.

CONTACT: Your Contacts: Merck: Media: Markus Talanow +49-6151-72-7144 /Investor Relations: +49-6151-72-3321. Pfizer: Media: Sally Beatty+1-212-733-6566 / Investor Relations: Ryan Crowe +1-212-733-8160

Mejora la comunicación de tu empresa con Europa Press Comunicación

Mejora la comunicación de tu empresa con Europa Press Comunicación

La actualidad más visitada en EuropaPress logo: La actualidad más vista
Esta web utiliza cookies propias y de terceros para analizar su navegación y ofrecerle un servicio más personalizado y publicidad acorde a sus intereses. Continuar navegando implica la aceptación de nuestra política de cookies -
Uso de cookies